Etizolam is a thienodiazepine compound licensed as a prescription anxiolytic and sedative in Japan (brand name Depas), India, and several other Asian countries, while simultaneously occupying the status of a heavily used research chemical in Western markets. It differs structurally from classical benzodiazepines in that the benzene ring of the diazepine core is replaced with a thiophene ring — a modification that does not alter the fundamental GABA-A receptor mechanism but does alter metabolic pathways and produce distinct pharmacokinetic characteristics. Etizolam is approximately 10 times more potent than diazepam on a milligram-for-milligram basis.
Etizolam has generated more community discussion, experience reports, and harm reduction discourse than virtually any other research chemical benzodiazepine — 34 Reddit posts in the database alone — reflecting both its widespread use and the significant addiction and dependence concerns it generates. Community experience is notably bifurcated: some users describe etizolam as an effective anxiolytic with a cleaner, less sedating profile than pharmaceutical benzodiazepines; many others document the rapid development of tolerance and physical dependence, sometimes after only weeks of use, with withdrawal described as protracted and severe.
The addictive potential of etizolam is a recurring and prominent theme in community accounts. The comparatively short half-life (approximately 6 hours), combined with high potency and rapid onset, produces an addiction profile that some users compare unfavorably to even alprazolam (Xanax) — itself considered among the more addictive pharmaceutical benzodiazepines. Multiple experience reports describe use escalating from therapeutic anxiety management to compulsive daily use over short periods. The Reddit corpus includes stark accounts of blackouts from combining etizolam with alcohol, failed attempts at self-managed withdrawal, and the use of etizolam as a harm reduction tool for opioid withdrawal — a practice that simply substitutes one dependence for another.
Safety at a Glance
High Risk- Frequency Is the Key Variable
- Never Combine with Alcohol
- Toxicity: Addiction Liability Etizolam's addiction potential is one of the most frequently discussed topics in community harm r...
- Dangerous with: 1,4-Butanediol, 2M2B, Acetylfentanyl, Alcohol (+59 more)
- Overdose risk: overdose is a medical emergency that may lead to a coma, permanent brain injury or death if not t...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 5 hrs – 7 hrsHow It Feels
Etizolam distinguishes itself from the benzodiazepine family through a quality best described as clarity. Within twenty to thirty minutes, the anxiety begins to lift, but instead of the foggy sedation that accompanies many of its relatives, what remains is a clean, functional calm. The mind does not slow so much as it stops racing. Thoughts that had been looping and overlapping settle into orderly single file, each one considered and released without the emotional amplification that anxiety typically provides. There is a lightness to this -- a feeling of unburdening, as though you had been carrying a heavy pack and someone had quietly lifted it from your shoulders.
The come-up enhances this functional anxiolysis with a gentle warmth and a subtle elevation of mood. The body relaxes, but not dramatically -- there is a pleasant looseness in the muscles, a softening of physical tension, but you remain coordinated and capable. Social interaction becomes notably easier: the self-monitoring and second-guessing that anxiety imposes on conversation simply stop, replaced by an easy confidence that feels natural rather than chemically imposed. There is a mild euphoria that manifests less as a high and more as the simple pleasure of feeling normal, of existing without the constant friction of an overactive threat-detection system.
At the peak, etizolam delivers its promised anxiolysis with an efficiency that can feel almost surgical. The anxiety is gone, comprehensively and specifically, leaving other mental faculties largely intact. You can think, plan, create, and converse with a freedom that those with chronic anxiety may have forgotten was possible. The sedation is present but manageable -- a slight heaviness behind the eyes, a gentle pull toward relaxation that can be overridden when necessary. Memory remains mostly intact, a notable contrast to more potent benzodiazepines, though fine details may be recorded with slightly less fidelity. The body is comfortable and warm, and there is an overall sense of well-being that makes the present moment feel perfectly adequate.
The comedown is smooth and relatively brief, reflecting the substance's shorter half-life. The calm fades over four to six hours, and the return of baseline anxiety is gradual rather than abrupt. There is no significant hangover, though some users report a mild rebound in anxiety the following day, as though the nervous system is compensating for its temporary vacation. The overall impression etizolam leaves is one of elegant functionality -- a precision tool rather than a sledgehammer.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(7)
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Insomnia— A persistent inability to fall asleep or maintain sleep despite physical tiredness, often characteri...
- Muscle relaxation— The experience of muscles throughout the body losing their rigidity and tension, becoming noticeably...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
Cognitive & Perceptual Effects
Visual(1)
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
Cognitive(10)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depersonalization— A detachment from one's own sense of self, body, or mental processes, as if observing oneself from o...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
Pharmacology
Mechanism of Action
Etizolam is a full agonist at the benzodiazepine binding site of GABA-A receptors, potentiating GABA-mediated chloride conductance. Like all benzodiazepine-site agonists, it acts as a positive allosteric modulator rather than a direct channel activator: it requires the presence of GABA to exert its effect but dramatically increases the frequency of channel opening when GABA binds. This GABAergic enhancement produces dose-dependent CNS depression across all benzodiazepine effect domains: anxiolysis (α2/α3 subunits), sedation and amnesia (α1 subunits), muscle relaxation (α2/α5 subunits), and anticonvulsant activity.
Thienodiazepine Structure and Potency
The thiophene ring substitution in etizolam's structure, combined with the 1,2 fusion geometry that distinguishes thienodiazepines from classical 1,4-benzodiazepines, yields a compound approximately 10 times more potent than diazepam by receptor binding affinity. Active doses of etizolam are in the range of 0.5–2 mg, compared to diazepam's 5–20 mg therapeutic range.
Pharmacokinetics
- Bioavailability: High by oral and sublingual routes
- Onset: 15–30 minutes oral, faster sublingually
- Peak plasma concentration: 1–2 hours
- Half-life: ~6 hours (parent compound)
- Active metabolites: α-hydroxyetizolam (active, contributes to extended effects)
- Total effective duration: 6–8 hours with aftereffects
The relatively short half-life compared to many benzodiazepines contributes to more pronounced inter-dose withdrawal and craving, which may underlie etizolam's high addiction liability.
Unique Properties
Some research suggests etizolam may have greater amnestic potential than clinically predicted from its receptor binding alone. Community reports of blackouts at recreational doses are more common than with some other benzodiazepines, including at doses that users describe as "normal." The mechanism of this may relate to the thiophene substitution's effects on distribution kinetics within the CNS.
Tolerance
Tolerance develops rapidly with regular etizolam use — some users report noticeable tolerance development within 1–2 weeks of daily dosing. This faster tolerance development than long-acting benzodiazepines, combined with a shorter half-life, creates more frequent dosing needs and a heightened cycle of tolerance-seeking escalation.
Detection Methods
Standard Drug Panel Inclusion
Etizolam is NOT included on standard 5-panel or 10-panel drug screens. As a thienodiazepine rather than a true benzodiazepine, etizolam has a thiophene ring that replaces the benzene ring found in classical benzodiazepines. This structural difference substantially reduces cross-reactivity with standard immunoassay antibodies. Most commercial benzodiazepine immunoassay platforms do not detect etizolam or its metabolites, producing false-negative results. However, some newer immunoassay formulations have been designed with improved cross-reactivity for thienodiazepines.
Urine Detection
Etizolam and its primary metabolite alpha-hydroxyetizolam are detectable in urine for approximately 2 to 5 days after a single dose. The parent compound has a half-life of approximately 3.5 hours, while the active metabolite alpha-hydroxyetizolam has a half-life of approximately 8 hours. Chronic users may test positive for up to 1 week. Reliable detection requires LC-MS/MS methods that specifically include etizolam and alpha-hydroxyetizolam in their analytical panel.
Blood and Serum Detection
Blood detection is possible for 1 to 3 days after use. Therapeutic blood concentrations range from 5 to 50 ng/mL. Etizolam is extensively metabolized by CYP3A4 and CYP2C18 enzymes. Blood analysis is particularly important in forensic contexts, as etizolam has been implicated in numerous drug-related deaths, especially in the United Kingdom and Japan.
Hair Follicle Detection
Hair testing for etizolam is feasible using LC-MS/MS methods, with detection windows up to 90 days. Both the parent compound and alpha-hydroxyetizolam are targeted in hair analysis.
Confirmatory Methods
LC-MS/MS is the definitive confirmatory method. The thienodiazepine structure requires that etizolam be specifically added to laboratory panels, as it will not appear on standard benzodiazepine confirmation testing. Reference standards are widely available. Several published forensic methods have been validated specifically for etizolam and its metabolites.
Reagent Testing
The Zimmermann reagent produces a weak yellow color with etizolam. Mandelin may produce a faint orange-brown response. These reactions are not reliable for identification at typical doses. Fentanyl test strips should always be used with etizolam products from unregulated sources, given documented contamination incidents.
Interactions
| Substance | Status | Note |
|---|---|---|
| 1,4-Butanediol | Dangerous | Combined CNS depression; risk of respiratory failure |
| 2M2B | Dangerous | Combined CNS depression; risk of respiratory failure |
| Acetylfentanyl | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Alcohol | Dangerous | Combined CNS depression; risk of respiratory failure |
| Alprazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Atropa belladonna | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Baclofen | Dangerous | Combined CNS depression; risk of respiratory failure |
| Benzodiazepines | Dangerous | Combined CNS depression; risk of respiratory failure |
| Buprenorphine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Cake | Dangerous | Combined CNS depression; risk of respiratory failure |
| Carisoprodol | Dangerous | Combined CNS depression; risk of respiratory failure |
| Clonazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Clonazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Clonidine | Dangerous | Combined CNS depression; risk of respiratory failure |
| Codeine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Datura | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Deschloroetizolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Desomorphine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Dextropropoxyphene | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Diazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Diclazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Dihydrocodeine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Diphenhydramine | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Eszopiclone | Dangerous | Combined CNS depression; risk of respiratory failure |
| Ethylmorphine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| F-Phenibut | Dangerous | Combined CNS depression; risk of respiratory failure |
| Fentanyl | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Flualprazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flubromazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flubromazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flunitrazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flunitrazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Gabapentin | Dangerous | Combined CNS depression; risk of respiratory failure |
| Gaboxadol | Dangerous | Combined CNS depression; risk of respiratory failure |
| GBL | Dangerous | Combined CNS depression; risk of respiratory failure |
| GHB | Dangerous | Combined CNS depression; risk of respiratory failure |
| Grayanotoxin | Dangerous | Combined CNS depression; risk of respiratory failure |
| Harmala alkaloid | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Heroin | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Hydrocodone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Hydromorphone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Kratom | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Lorazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| MAOI | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Mephenaqualone | Dangerous | Combined CNS depression; risk of respiratory failure |
| Methadone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Methaqualone | Dangerous | Combined CNS depression; risk of respiratory failure |
| Metizolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Midazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Mirtazapine | Dangerous | Combined CNS depression; risk of respiratory failure |
| Morphine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Myristicin | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Naloxone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Nicotine | Dangerous | Combined CNS depression; risk of respiratory failure |
| Nifoxipam | Dangerous | Combined CNS depression; risk of respiratory failure |
| O-Desmethyltramadol | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Oxycodone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Oxymorphone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Peganum harmala | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Pentobarbital | Dangerous | Combined CNS depression; risk of respiratory failure |
| Pethidine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Phenobarbital | Dangerous | Combined CNS depression; risk of respiratory failure |
| SAMe | Dangerous | Combined CNS depression; risk of respiratory failure |
| 2-Aminoindane | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 2-FA | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 2-FEA | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 2-Fluorodeschloroketamine | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 2-FMA | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 1,3-Butanediol | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 1B-LSD | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 1cP-AL-LAD | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 1cP-LSD | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 1cP-MiPLA | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
History
Pharmaceutical Development in Japan
Etizolam was first synthesized in 1969 and developed by Yoshitomi Pharmaceutical Industries in Japan. It received pharmaceutical approval in Japan in 1983 under the brand name Depas for the treatment of anxiety disorders, neurosis, and as a sleep aid. It subsequently received approval in India and several other countries. Etizolam is distinguished from most research chemical benzodiazepines in being a genuinely characterized pharmaceutical product with clinical safety and efficacy data — albeit primarily from the Japanese literature.
Western Research Chemical Market
Despite its pharmaceutical status in Japan, etizolam was not approved by regulatory agencies in Western countries, where it occupied legal gray areas. Its emergence in Western research chemical markets accelerated from approximately 2010 onward, facilitated by online vendors and the difficulty of scheduling a compound with legitimate pharmaceutical applications in other jurisdictions. At its peak, etizolam was among the most widely used research chemical depressants in the United States and Europe.
Regulatory Actions
Responding to increasing community reports of dependence, overdose, and deaths involving novel benzodiazepines including etizolam, regulatory agencies progressively moved to schedule it. The UK's Psychoactive Substances Act 2016 effectively banned all novel psychoactive substances. In the United States, several states scheduled etizolam individually before the DEA placed it on Schedule I in 2023. India significantly tightened prescribing controls and import restrictions in 2017.
Legacy
Etizolam's trajectory — legitimate pharmaceutical compound to widely used research chemical to scheduled substance — illustrates the broader regulatory and harm reduction challenges posed by novel psychoactive substances. Its 34-post Reddit corpus reflects a genuinely engaged community harm reduction discourse around one of the most clinically significant benzodiazepine-class research chemicals of the 2010s.
Harm Reduction
Frequency Is the Key Variable
Etizolam's harm reduction profile is heavily dominated by frequency concerns. Once-weekly or less use is relatively manageable in terms of dependence risk; daily use over weeks reliably produces physical dependence. The most important harm reduction intervention is strict limitation of use frequency — many experienced users recommend no more than twice per week maximum, with weeks off between periods of use.
Accurate Dosing
At 10x diazepam potency, etizolam doses are typically in the sub-milligram to few-milligram range. Powder forms require a milligram-accurate scale (0.001g precision) or volumetric solution dosing. Many community overdoses involve underestimated amounts of etizolam powder.
Never Combine with Alcohol
The blackout risk from etizolam plus alcohol is exceptionally high, even at doses that individually would not produce blackout. Alcohol also potentiates all CNS depressant effects. This combination should be treated as categorically off-limits.
Plan Against Compulsive Redosing
Etizolam's pleasant onset and relatively short duration create risk of compulsive redosing — taking additional doses before the first has fully offset. This pattern accelerates tolerance and dependence. Having a predetermined dose plan with a defined endpoint, and ideally not having additional etizolam accessible during use, reduces this risk.
Taper Protocol for Dependent Users
Those who have developed physical dependence should not abruptly discontinue. A medically supervised taper using a long-acting equivalent (e.g., diazepam) is strongly recommended. Community-based taper calculators using Ashton-equivalent conversion ratios are available, but medical supervision significantly reduces seizure risk.
Track Use in a Log
Given the high dependence liability, keeping a written log of use frequency, dose, and notable effects helps identify escalating patterns before they become compulsive. Difficulty sticking to a planned schedule is an early warning sign.
Toxicity & Safety
Addiction Liability
Etizolam's addiction potential is one of the most frequently discussed topics in community harm reduction discourse. The combination of high potency, relatively short half-life (producing noticeable inter-dose effects), and pleasant onset profile creates high addiction liability. Community accounts consistently describe rapid escalation from occasional use to daily dependence, often within 4–8 weeks.
The short half-life means more frequent dosing is needed to maintain effect relative to long-acting benzodiazepines like diazepam or clonazepam, which accelerates the cycle of use and reinforces compulsive dosing patterns.
Physical Dependence and Withdrawal
Physical dependence develops readily with regular etizolam use. Withdrawal from etizolam dependence can be severe and life-threatening:
- Early withdrawal (12–24 hours after last dose): Anxiety, insomnia, tremor, agitation
- Peak withdrawal (2–4 days): Tachycardia, diaphoresis, severe anxiety, perceptual disturbances
- Seizure risk: Grand mal seizures are a documented risk of untreated benzodiazepine withdrawal; particularly dangerous given etizolam's relatively short half-life producing more abrupt withdrawal dynamics
- Protracted withdrawal: Some users report ongoing anxiety, insomnia, cognitive symptoms, and depersonalization for months after acute withdrawal
Blackout Risk
Community reports describe blackout (anterograde amnesia) from etizolam with some frequency, including at doses not typically associated with such effects. Blackouts from combined etizolam and alcohol use are particularly well-documented. Blacked-out individuals may continue to consume additional substance, greatly amplifying overdose risk.
Respiratory Depression with CNS Depressants
Like all benzodiazepines, etizolam in combination with opioids or alcohol can produce fatal respiratory depression. The Reddit corpus includes mentions of combining etizolam with other substances for potentiation — a practice that meaningfully increases fatality risk.
Drug Interactions
- Alcohol — Dramatically increases blackout risk and respiratory depression
- Opioids — High-risk combination; FDA black box warning class
- CYP3A4 inhibitors — Increase etizolam plasma levels
- Other benzodiazepines — Additive and potentially synergistic effects
Addiction Potential
highly addictive with a high potential for abuse
Overdose Information
overdose is a medical emergency that may lead to a coma, permanent brain injury or death if not treated promptly and properly.
Symptoms of a thienodiazepine overdose may include severe thought deceleration, slurred speech, confusion, delusions, respiratory depression, coma or death. Thienodiazepine overdoses may be treated effectively in a hospital environment, with generally favorable outcomes. Thienodiazepine overdoses are sometimes treated with flumazenil, a GABAA antagonist. However, care is primarily supportive in nature.
- Depressants** (1,4-Butanediol, 2-methyl-2-butanol, alcohol, barbiturates, GHB/GBL, methaqualone, opioids) - This combination can result in dangerous or even fatal levels of respiratory depression. These substances potentiate the muscle relaxation, sedation and amnesia caused by one another and can lead to unexpected loss of consciousness at high doses. There is also an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
- Dissociatives** - This combination can result in an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
- Stimulants** - It is dangerous to combine thienzodiazepines with stimulants due to the risk of excessive intoxication. Stimulants mask the sedative effect of thienzodiazepines, which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of thienzodiazepines will be significantly increased, leading to intensified disinhibition. If combined, one should strictly limit themselves to only dose a certain amount of thienzodiazepines per hour. This combination can also potentially result in severe dehydration if hydration is not monit
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Unpredictable potentiation of CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Tolerance
| Full | within a couple of days of continuous use |
| Half | Unknown |
| Zero | 7 - 14 days |
Cross-tolerances
Legal Status
Legal Status
Etizolam occupies a uniquely complex legal position globally, having transitioned from an uncontrolled research chemical to an internationally scheduled substance over the course of a decade.
United Nations
On March 4, 2020, the United Nations Commission on Narcotic Drugs (CND), during its 63rd Session, voted to place etizolam inSchedule IV of the 1971 Convention on Psychotropic Substances, bringing it under international control for the first time. This scheduling was based on a critical review by the WHO Expert Committee on Drug Dependence, which found sufficient evidence of abuse potential and public health harm .
United States
At the federal level, the DEA temporarily placed etizolam inSchedule I of the Controlled Substances Act effective July 26, 2023, under emergency scheduling authority. This temporary order, initially set to expire in July 2025, has been extended throughJuly 26, 2026. A final rule to permanently schedule etizolam (along with clonazolam, diclazepam, flualprazolam, and flubromazolam) in Schedule I is under review .
Prior to federal action, numerous individual states had already scheduled etizolam independently, including Alabama, Arkansas, Florida, Georgia, Indiana, Louisiana, Mississippi, Ohio, South Carolina, and Virginia, among others. These state-level classifications vary in specifics but generally place etizolam in Schedule I or its state-level equivalent .
Japan and India
Etizolam is a prescription pharmaceutical in Japan (marketed as Depas) and India (marketed as Etilaam, Etizest, and others). In these countries it is legally manufactured and prescribed for anxiety disorders, insomnia, and muscle tension. India has historically been a significant source of pharmaceutical-grade etizolam diverted to international markets .
United Kingdom
Etizolam is controlled as a Class C drug under the Misuse of Drugs Act 1971 and is listed inSchedule 1 under the Misuse of Drugs Regulations 2001, meaning it has no recognized medical use in the UK. It is additionally covered by thePsychoactive Substances Act 2016, which broadly prohibits the production, supply, and import of psychoactive substances not specifically exempted .
European Union
Etizolam was assessed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) after its first detection in 2011. Multiple EU member states have implemented national controls, and several have reported etizolam-associated fatalities .
References
UNODC Early Warning Advisory. Recently scheduled benzodiazepines: Flualprazolam and Etizolam. March 2020. Federal Register. Schedules of Controlled Substances: Temporary Placement of Etizolam in Schedule I. 88 FR 36375. June 2, 2023. Federal Register. Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I. 2025-14022. July 25, 2025. DEA Diversion Control Division. Etizolam Drug and Chemical Information. deadiversion.usdoj.gov. Fracasso C et al. Etizolam: A rapid review on pharmacology, non-medical use and harms. Drug Alcohol Depend. 2020;212:108029. Humphries C. The United Kingdom's Psychoactive Substances Act 2016: Where are we now? J Psychopharmacol. 2022;36(11):1223-1228. EMCDDA. European Drug Report: New psychoactive substances. 2020.
Experience Reports (2)
Tips (10)
The single most dangerous aspect of etizolam is the 'delusion of sobriety' — you genuinely believe you are not impaired and decide to take more. This is how blackouts happen. The community joke about 'etiboblamn not workibg' exists because people type gibberish while convinced they are sober. Pre-measure your dose and lock the rest away.
If you have developed physical dependence on etizolam, do NOT stop cold turkey. Benzodiazepine and thienodiazepine withdrawal can cause fatal seizures. Taper gradually, reducing by no more than 10-15% per week. Studies suggest etizolam may build tolerance slightly less rapidly than classical benzos, but dependence still develops.
Always dose etizolam volumetrically. Dissolve a known quantity in propylene glycol (PG) at a concentration like 5mg/ml, and dose with a graduated oral syringe. Etizolam powder is active at sub-milligram levels and cannot be safely eyeballed. PG solutions remain stable for months at room temperature.
Using etizolam 1-3 times per month with at least a week between uses is unlikely to cause physical dependence for most people. The moment you start using it multiple days in a row or using it to manage daily anxiety, you are on the path to dependence. Track your use in a journal.
Research chemical benzodiazepines (clonazolam, flualprazolam, etc.) are significantly more potent than pharmaceutical Etizolam. Doses measured in micrograms can cause multi-day blackouts. Use volumetric dosing.
If prescribed Etizolam, use it as directed and have honest conversations with your doctor about any recreational use. Benzodiazepines are among the most difficult drugs to quit once dependent. Short-term use only.
Community Discussions (12)
See Also
References (3)
- PubChem: Etizolam
PubChem compound page for Etizolam (CID: 3307)
pubchem - Etizolam - TripSit Factsheet
TripSit factsheet for Etizolam
tripsit - Etizolam - Wikipedia
Wikipedia article on Etizolam
wikipedia